141184-47-6

Basic information

• Product Name: Benzenemethanol, 3-(cyclopentyloxy)-4-methoxy-a-methyl-
• Synonyms: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANOL
• CAS NO: 141184-47-6
• Molecular Formula: C14H20O3
• Molecular Weight: 236.311
• Mol File: 141184-47-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 123-125 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• Boiling Point: 361.3±37.0 °C(Predicted)
• Density: 1.108±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzenemethanol, 3-(cyclopentyloxy)-4-methoxy-a-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3-(cyclopentyloxy)-4-methoxy-a-methyl-(141184-47-6)
• EPA Substance Registry System: Benzenemethanol, 3-(cyclopentyloxy)-4-methoxy-a-methyl-(141184-47-6)

Safety Data

• Hazardous Substances Data: 141184-47-6(Hazardous Substances Data)

Upstream product

• 676-58-4 methylmagnesium chloride 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 
• 75-16-1 methylmagnesium bromide 
• 121-33-5 vanillin 
• 137-43-9 Cyclopentyl bromide 
• 621-59-0 isovanillin 
• 74-88-4 methyl iodide 
• 917-54-4 methyllithium 

Downstream Products

• 1172617-18-3 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 1334336-03-6 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(3-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 1334336-04-7 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-p-tolyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 1334336-05-8 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 141184-48-7 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-ethanone 

Relevant articles and documents

Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics

A new series of catechol hydrazines was synthesized and their structure-activity relationship (SAR) was analyzed for developing an effective phosphodiesterase 4 (PDE4) inhibitor as an anti-asthmatic drug candidate. Among the (E)-Analogues tested using in

Safety and Efficacy of New 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine Analogs as Potential Phosphodiesterase-4 Inhibitors in NIH-3T3 Mouse Fibroblastic Cells

A novel series of potential phosphodiesterase-4 (PDE-4) inhibitors, 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, were developed. Different concentrations of the synthesized compounds were tested on cultured NIH-3T3 cells to determine their safety and efficacy in NIH-3T3 mouse fibroblastic cells in comparison with rolipram, a selective PDE-4 inhibitor. The viability of cells was determined by (3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazoliumbromide (MTT) assay. The PDE inhibition rate was measured indirectly by determination of concentrations of extracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) using enzyme-linked immunoassay technique. The results showed that all tested compounds caused a marked increase in the concentration of cAMP, whereas the concentration of cGMP stayed approximately unchanged. The cytotoxic IC50 of all synthesized compounds was approximately twofold greater than their required concentration for inhibition of PDE-4 (in terms of elevation of cAMP), and thus, these structures could be used to develop potent and safe inhibitors of PDE-4 enzyme.

Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde

Processes for coupling phenol and cycloalkyls including combining an optionally substituted phenol, a cycloalkyl substituted with a leaving group, carbonate salt, tetrahydrofuran, and an optional phase transfer agent are provided. Also provided are proces